© Reuters. Logo is pictured during the 152nd Annual General Meeting of Nestle in Lausanne

By Michael Shields

ZURICH (Reuters) – Nestle SA (SIX:) has entered exclusive negotiations to sell its skin health business to a consortium led by EQT Partners and Abu Dhabi’s ADIA in a deal worth 10.2 billion Swiss francs ($10.12 billion), it said on Thursday.

The proposed transaction with private equity firm EQT and a unit of the Abu Dhabi Investment Authority was expected to close in the second half of 2019, pending regulatory approval, it said.

Nestle will provide an update on how it will use the proceeds and its future capital structure at that time, the world’s biggest packaged food group said in a statement.

Nestle shares were indicated 0.6% higher in pre-market activity.

Reuters and the Financial Times had reported on Wednesday that EQT was putting the finishing touches to the deal.

Nestle Chief Executive Mark Schneider put the skin health unit up for sale last September as the group moved to ditch underperforming businesses in an effort to fend off criticism from an activist investor who wanted an overhaul.

Nestle Skin Health, which sells Cetaphil and Proactiv skin care products, Restylane wrinkle fillers and prescription dermatology medicines, had sales of 2.8 billion Swiss francs last year.

Nestle created the unit in 2014 when it bought out L’Oreal’s stake in their Galderma joint venture.

Under former Chief Executive Paul Bulcke, skin treatments were part of Nestle’s push into higher-growth health products to counter a slowdown in its traditional food business.

READ  Belgium shares lower at close of trade; BEL 20 down 1.51%

But the unit has performed poorly, leading to one-off costs and restructuring.

EQT and ADIA had faced competition from rival buyout funds and some industry players including a consortium of Advent and Cinven, as well as U.S. private equity firm KKR & Co Inc and European fund PAI Partners, sources had said.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.





READ SOURCE

WHAT YOUR THOUGHTS

Please enter your comment!
Please enter your name here